

YALE SCHOOL OF MEDICINE - HUMAN INVESTIGATION COMMITTEE
Tissue and Consent for Banking and/or Secondary Uses Checklist
(Version 1.3 Draft 12.6.04)

CHECKLIST

Investigators are encouraged to use the “Banking Checklist” to help identify the required consent elements when drafting an ICD that includes the banking of data or biologic samples for future research studies.

Consent Elements Checklist For Storage of Data or Biologic Samples for Future Use				
1. General Format/Style Issues		Yes	No	N/A
	<p>If the permission to bank biological samples or data is combined with the informed consent document (ICD) used to obtain consent for participation in a research trial proceed to Section 2.</p> <p>If the consent for banking is separate from that consent form approved for the primary study, is the consent form formatted with the proper headers (Study title, name of Principal Investigator, HIC#, Funding Source) and page numbers, using the HIC template?</p>			
	Is the consent form written in lay language that will be readily understood by the intended audience?			
	Is medical jargon avoided, and are any/all technical terms fully explained?			
	Is the consent form legible, written in at least 12-point font, and properly spaced?			
2. Invitation/ Description of Banking and Secondary Uses				
	Does the consent form use the second person (you, your, etc.) throughout?			
	Is the potential subject clearly invited to donate tissue or data to a repository for future research purposes?			
	Does the paragraph briefly (in a few sentences) specify the nature and purposes of the future research in general terms (e.g., development, cancer, brain biology, mental illness behavior, heart function, heart disorders)?			
	Is the potential subject clearly informed why he or she has been invited for participation?			
3. Description of				

YALE SCHOOL OF MEDICINE - HUMAN INVESTIGATION COMMITTEE
Tissue and Consent for Banking and/or Secondary Uses Checklist
(Version 1.3 Draft 12.6.04)

Procedures				
	Does the ICD include a clear description of the operation of the repository?			
	Does the ICD include a clear description of the conditions under which data or specimens will be released for future research purposes to the investigators who are listed on the banking protocol?			
	Does the ICD include a clear description of the conditions under which data or specimens will be released for future research purposes to recipient investigators who are not affiliated with the banking protocol?	Yes	No	N/A
	Does the ICD note that recipient investigators will receive the data or specimens after receiving approval by an IRB ?			
4. Risks and Inconveniences				
	Does the investigator clearly describe potential risks associated with banking (e.g. potential loss of privacy)?			
	When appropriate, does the consent form include a statement that the future research may involve risks that are currently unforeseeable?			
	Where future human genetic research is anticipated, does the ICD include information about the consequences of DNA analysis (e.g., disease prediction, if probability is high; possible discrimination; possible determination of paternity or other family relationships)?			
5. Benefits				
	Does the consent form clearly describe any expected benefits to the subject as a result of the banking activity? (If there is no individual benefit, the consent form should state this).			
	Does the consent form clearly describe any benefits expected to accrue to the population the subject represents or to society in general as a result of future research studies?			
6. Economic Considerations				
	Does the ICD note that subjects will not be compensated for donating their data or biologic samples to the repository?			
	Does the ICD note that subjects will not be compensated for the use of their data or biologic samples in future			

YALE SCHOOL OF MEDICINE - HUMAN INVESTIGATION COMMITTEE
Tissue and Consent for Banking and/or Secondary Uses Checklist
(Version 1.3 Draft 12.6.04)

	research studies?			
	Does the ICD note that there are no plans to compensate the donors of data/specimens should the future use of said samples result in a profitable product?			
7. Alternatives to Participation				
	Does the ICD note that the subject need not participate in the banking arm or protocol in order to participate in a primary clinical trial or research study?			
8. Confidentiality		Yes	No	N/A
	Does the consent form provide a thorough outline of the procedures in place to ensure the confidentiality both of subjects' participation, as well as their data?			
	Certificate of Confidentiality is recommended by OHRP for the repository operations. Does the consent form state this, as well as providing a description of the extra protection (and limitations to such protection) that is afforded?			
	Does the consent form list any agencies or persons (such as the study sponsor, members of the HIC, or regulatory agencies) who will have access to study records?			
	Does the study involve diagnostic or genetic testing? If so, are the relevant confidentiality issues (how will samples be stored, withdrawal of samples, plans for return of information to subjects, etc.) addressed?			
9. In Case of Injury				
	For studies posing minimal risk to subjects, this section may be omitted. Do you believe it is appropriate to omit the section? If the section is included and you have informed the subject that compensation for injury is not available, have you also noted that the subject does not give up any legal rights by signing consent?			
10. Voluntary Participation				
	Is the potential donor-subject informed that his or her participation is voluntary, and that he or she may withdraw from the study at any time?			
	Is the potential donor-subject informed that his or her data or specimens will continue to be used in secondary uses for which the data or specimens were released prior to the donor-subject indicating that he/she no longer wished to have identified data shared for future uses?			
	Does the ICD indicate whether the identifiable data or samples will be destroyed or de-identified and whether the			

YALE SCHOOL OF MEDICINE - HUMAN INVESTIGATION COMMITTEE

Tissue and Consent for Banking and/or Secondary Uses Checklist

(Version 1.3 Draft 12.6.04)

	subject has a choice between these alternatives if both exist? If de-identified, is the subject-donor informed that data or samples may continue to be used?			
11. Questions				
	Is the potential subject offered the chance to discuss the study with the investigator (or his or her designee), and to ask any questions he or she may have?			
12. Miscellaneous				
	For studies involving non-English speaking subjects, has the ICD been translated into all relevant languages?			
	Does the banking of data include information from any "secondary subjects," for whom a separate consent form should be developed?			